Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
NCT02060383 on ClinicalTrials.gov · last registry update 2019-05-29
An unusually large phase 4: 249 participants, more than double the 75 typical for the stage. The sponsor logged completion for 5 February 2018. Primary outcome, as filed: Change in HbA1c From Randomization to Approximately 16 Weeks.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Enrollment
- 249
- Started
- 2014-05-23
- Primary completion
- 2018-02-05 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in HbA1c From Randomization to Approximately 16 Weeks
Conditions studied
Cushing's Disease · Acromegaly
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.